Q-Line BiotechNSE:QLINE -5.15%12 EBIT per Share is ₹ as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Q-Line Biotech ranks worse than 144927.39% on this metric.
Q-Line Biotech's EBIT per Share for the
six
months ended in Mar. 2025 was ₹24.63.
Q-Line Biotech does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025.
During the past 12 months, the average EBIT per Share Growth Rate of Q-Line Biotech was 100.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Q-Line Biotech's EBIT per Share or its related term are showing as below:
NSE:QLINE's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Q-Line Biotech's EBIT for the
six
months ended in Mar. 2025 was ₹575 Mil.
Q-Line Biotech (NSE:QLINE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Q-Line Biotech EBIT per Share Related Terms
Q-Line Biotech EBIT per Share Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a EBIT per Share of ₹ as of Mar. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Q-Line Biotech and its competitors. According to the industry distribution chart, Q-Line Biotech ranks #999999 out of 690 companies in the Medical Devices & Instruments industry.
Is Q-Line Biotech's EBIT per Share too high?
Q-Line Biotech's current EBIT per Share is ₹. Based on the distribution chart, Q-Line Biotech ranks #999999 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #999999 out of 690 companies for EBIT per Share. This places Q-Line Biotech in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current EBIT per Share is ₹. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current EBIT per Share of ₹. The current EBIT per Share is ₹. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current EBIT per Share is ₹ as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 